3. CareDx Inc. (NASDAQ:CDNA)
CareDx, Inc. (NASDAQ: CDNA) is a more specialized biotech and diagnostics stock, but that specialization is exactly what makes it interesting. The company focuses on transplant diagnostics, digital health, and precision medicine tools for transplant patients and caregivers. Based on latest market data, CareDx traded at $19.97, with a market capitalization of about $1.06 billion. In the uploaded screen, CareDx showed a 6.22% 12-week price change, a forward P/E of 22.69, projected EPS growth of 51.72%, and projected sales growth of 19.80%. That makes CDNA a smaller, higher-risk name, but one with a clearer turnaround profile than many speculative biotech stocks.
The Q1 2026 numbers were encouraging. CareDx reported total revenue of $118 million, up 39% from $85 million in Q1 2025. Testing services revenue increased 48% to $91 million, while testing services volume rose 17% to approximately 54,900 tests. Patient and digital solutions revenue also increased 33% to $16 million. The company raised 2026 revenue guidance to $447 million to $465 million and raised adjusted EBITDA guidance to $43 million to $57 million, signaling that management sees the growth trend continuing.
CEO John W. Hanna said the company delivered “another quarter of record growth,” driven by momentum in Precision Medicine Testing Services and Patient and Digital Solutions. He also pointed to strategic moves around AlloHeme and the planned divestiture of the Lab Products business, which is intended to simplify the operating model and improve adjusted EBITDA margins. That is the real investment angle: CareDx is trying to become more focused, more profitable, and more clearly tied to high-value transplant monitoring. The risk is reimbursement. Transplant diagnostics can be affected by Medicare policy, payer behavior, hospital budgets, and competing tests. But if CareDx keeps growing testing revenue while improving profitability, CDNA could remain one of the more compelling small-cap biotech turnaround stories.
Click next to see the following stock...
